Aberdeen Group plc Sells 88,637 Shares of Arcutis Biotherapeutics, Inc. $ARQT
Aberdeen Group plc reduced its stake in Arcutis Biotherapeutics (NASDAQ:ARQT) by 13.1% in Q4 2025, selling 88,637 shares and now owning 586,397 shares valued at $17.03 million. Other institutional investors showed mixed activity, while insiders like Todd Watanabe and Howard Welgus also sold a total of 159,546 shares. Despite insider sales, Arcutis Biotherapeutics beat Q4 earnings and revenue expectations, and analysts maintain a "Moderate Buy" rating with an average $34 price target.
Insider Sell: Howard Welgus Sells 10,000 Shares of Arcutis Bioth
Howard Welgus, a Director at Arcutis Biotherapeutics Inc (ARQT), sold 10,000 shares of the company on April 1, 2026, reducing his holdings to 39,744 shares. This transaction is part of a larger trend of insider selling at ARQT over the past year, with 56 insider sells compared to 6 insider buys. The stock is currently trading at $23.88, which is modestly undervalued compared to its GF Value of $30.94.
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Director Sells 10,000 Shares of Stock
Arcutis Biotherapeutics Director Howard Welgus sold 10,000 shares of ARQT stock for $238,800 on April 1st, reducing his stake by 20.1%. This transaction, executed under a Rule 10b5-1 trading plan, leaves him with 39,744 shares. The company recently surpassed quarterly EPS and revenue expectations but still faces negative margins, with analysts currently holding a "Moderate Buy" consensus rating and an average price target of $34.
Planned sale: Arcutis (ARQT) director disposes of 10,000 shares
Arcutis Biotherapeutics director Howard G. Welgus reported an open-market sale of 10,000 shares of common stock at a weighted average price of $23.8801 per share. This transaction, executed on April 1, 2026, was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2025. Following the sale, Welgus directly holds 39,744 shares of Arcutis common stock.
Assessing Arcutis Biotherapeutics (ARQT) Valuation After Positive ZORYVE Infant Phase 2 Trial Results
Arcutis Biotherapeutics (ARQT) is under valuation scrutiny following positive Phase 2 trial results for its ZORYVE cream in infants with atopic dermatitis, which supports a planned supplemental New Drug Application. Despite recent stock volatility, the company shows strong long-term shareholder returns and is assessed as undervalued by analysts. The valuation hinges on ZORYVE's growth potential and its favorable safety profile for pediatric use.
Insider sales reported at Arcutis Biotherapeutics (NASDAQ: ARQT) — two 10,000-share disposals
Arcutis Biotherapeutics (NASDAQ: ARQT) reported two proposed sales of common stock by Howard Welgus, each for 10,000 shares, through a Form 144 filing. The sales occurred on March 2, 2026, for $256,517.50 and on February 2, 2026, for $250,482.69. The filing also references 10,000 shares tied to a stock option exercise from June 4, 2018, indicating routine insider liquidity reporting.
Analysts Are Optimistic We'll See A Profit From Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Analysts are predicting Arcutis Biotherapeutics (NASDAQ:ARQT) will turn a profit in 2026, a significant improvement from previous loss forecasts. The company recently received FDA approval for a new product, which is expected to drive substantial revenue growth and help achieve profitability within three years. Despite a negative share price performance over the past year, these revised analyst expectations suggest a positive outlook for the company's financial future.
Arcutis executives join Needham virtual health conference April 14
Arcutis Biotherapeutics (Nasdaq: ARQT) management will present at the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026. The company will host a Fireside Chat on April 14, 2026, at 11:00 AM ET, with a live webcast available on its website and a replay accessible for 180 days. Despite a series of positive news updates recently, including clinical data and development progress, the company's stock has historically shown negative or muted price reactions following such announcements.
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference
Arcutis Biotherapeutics, Inc. announced that its management will be presenting at the 25th Annual Needham Virtual Healthcare Conference, scheduled from April 13-16, 2026. The company, focused on immuno-dermatology innovations, will hold a fireside chat on April 14, 2026, at 11:00 am ET. A webcast of the presentation and its replay will be available on Arcutis's website.
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference
Arcutis Biotherapeutics, Inc. announced that its management will present at the 25th Annual Needham Virtual Healthcare Conference, scheduled for April 13-16, 2026. The presentation will be a fireside chat on Tuesday, April 14, 2026, at 11:00 am ET, with a webcast available on the company’s website. Arcutis is a commercial-stage biopharmaceutical company focusing on innovations in immuno-dermatology.
Zevenbergen Capital Investments LLC Acquires Shares of 418,035 Arcutis Biotherapeutics, Inc. $ARQT
Zevenbergen Capital Investments LLC initiated a new position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) during the fourth quarter, purchasing 418,035 shares valued at approximately $12.14 million. This move represents a 0.34% ownership in the company. Despite recent insider selling, other institutional investors have also increased their stakes, holding a "Moderate Buy" consensus rating with an average price target of $34.00, while analysts forecast a negative full-year EPS.
Tudor Investment Corp ET AL Invests $1.32 Million in Arcutis Biotherapeutics, Inc. $ARQT
Tudor Investment Corp ET AL has initiated a new position in Arcutis Biotherapeutics (NASDAQ:ARQT), purchasing 69,980 shares valued at approximately $1.32 million. Despite recent insider selling totaling $4.20 million, analysts maintain a "Moderate Buy" consensus with an average price target of $34.00, especially after the company exceeded quarterly expectations with EPS of $0.13 and revenue of $129.5 million. The company focuses on developing therapies for immuno-inflammatory skin diseases.
How New Infant Atopic Dermatitis Data And sNDA Plans At Arcutis (ARQT) Have Changed Its Investment Story
Arcutis Biotherapeutics (ARQT) recently presented positive Phase 2 data for ZORYVE in infant atopic dermatitis and plans to submit a supplemental New Drug Application. This move aims to expand ZORYVE's addressable patient population and strengthen its position as a non-steroidal treatment across age groups. While the data supports the company's growth narrative, investors should be aware of the concentration risk around ZORYVE as the primary revenue driver.
Arcutis Biotherapeutics Shares Phase 2 Trial Results on Topical Treatment for Infants with Mild to Moderate Atopic Dermatitis
Arcutis Biotherapeutics presented positive Phase 2 trial results for its topical treatment for infants aged three months to less than two years with mild to moderate atopic dermatitis. The study, shared at the 2026 American Academy of Dermatology Annual Meeting, showed favorable safety and tolerability profiles, along with improvements in itch and skin inflammation. Specific data points were not fully disclosed during the presentation.
Arcutis Biotherapeutics Reports Positive Phase 2 Trial Results for ZORYVE® Cream in Infants with Atopic Dermatitis
Arcutis Biotherapeutics announced positive Phase 2 trial results for its ZORYVE® (roflumilast) cream 0.05% in treating mild to moderate atopic dermatitis in infants aged 3 to less than 24 months. The study demonstrated the cream's safety and efficacy, with caregivers reporting rapid itch relief in nearly half of the infants within 10 minutes of application. These findings support Arcutis' plans to submit a supplemental New Drug Application for ZORYVE cream in this age group, reinforcing the drug's potential as an important treatment option.
Arcutis Biotherapeutics Reports Positive Phase 2 Trial Results for ZORYVE® Cream in Infants with Atopic Dermatitis
Arcutis Biotherapeutics announced positive Phase 2 trial results for its ZORYVE® (roflumilast) cream 0.05% in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis. The trial demonstrated the cream's safety and efficacy, showing rapid itch relief within 10 minutes for nearly half of the infants and significant symptom improvement. These findings support the company's plan to submit a supplemental New Drug Application for ZORYVE cream for this age group in the second quarter of 2026.
Nearly half of infants saw eczema itch ease in 10 minutes
Arcutis (Nasdaq: ARQT) announced new Phase 2 data from the INTEGUMENT-INFANT trial for its investigational ZORYVE cream 0.05% in infants aged 3 to less than 24 months with mild to moderate atopic dermatitis. The study showed meaningful improvements in signs and symptoms of eczema, with 46.6% of infants experiencing itch relief within 10 minutes, and the treatment was well-tolerated. These results support Arcutis's plan to submit a supplemental New Drug Application for ZORYVE cream 0.05% for this age group in Q2 2026.
Arcutis Biotherapeutics (ARQT) price target increased by 10.24% to 35.70
The article reports that the price target for Arcutis Biotherapeutics (ARQT) has been increased by 10.24%, reaching $35.70. This update indicates a positive adjustment in analyst expectations for the company's stock valuation.
[SCHEDULE 13G/A] Arcutis Biotherapeutics, Inc. Amended Passive Investment Disclosure
The Vanguard Group filed an amended Schedule 13G/A for Arcutis Biotherapeutics, Inc. (ARQT), reporting beneficial ownership of 0 shares of Common Stock, representing 0% of the class. This change reflects an internal realignment within The Vanguard Group effective January 12, 2026, where subsidiaries will now report beneficial ownership separately. The filing confirms that The Vanguard Group no longer has, or is deemed to have, beneficial ownership over securities held by these realigned subsidiaries.
Arcutis Biotherapeutics (ARQT) Valuation Check After New Pediatric ZORYVE Phase 3 Extension Data
Arcutis Biotherapeutics (ARQT) is being re-evaluated after new Phase 3 extension data for its ZORYVE cream in pediatric atopic dermatitis was published. Despite recent share price cooling, the stock has strong multi-year returns and is trading below some intrinsic value estimates. A key narrative suggests the stock is 44.5% undervalued, with a fair value of $39.99, hinging on ZORYVE's continued uptake and the progress of roflumilast.
Arcutis (ARQT) announces long-term phase 3 data for ZORYVE cream in children
Arcutis has announced positive long-term phase 3 data for its ZORYVE cream when used in children aged 2-11 with mild, moderate, or severe plaque psoriasis. The study found consistent safety and high tolerability, with approximately half of the patients achieving clear or almost clear skin within 8 weeks. These results support the potential for ZORYVE as an effective and well-tolerated treatment option for pediatric plaque psoriasis.
Arcutis (ARQT) announces long-term phase 3 data for ZORYVE cream in children
Arcutis has announced positive long-term phase 3 data for its ZORYVE cream when used in children aged two to 12 years with mild, moderate, or severe plaque psoriasis. The study found consistent safety and efficacy over 52 weeks, with high rates of treatment success and significant improvements in skin clearance, even in sensitive areas. This data supports ZORYVE as a potential steroid-free treatment option for pediatric psoriasis.
A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Weakness
Arcutis Biotherapeutics (ARQT) shares have seen recent weakness but maintain a positive one-year return, prompting an evaluation of its valuation. The company's fair value is estimated at $39.99, significantly higher than its current $22.24, largely due to the potential of its non-steroidal drug ZORYVE for both pediatric and adult dermatological patients. Investors are encouraged to review rewards and warning signs, as well as consider key risks such as potential slowdowns in ZORYVE adoption.
Arcutis (ARQT) Announces Long-Term Phase 3 Data for ZORYVE Cream in Children
Arcutis Biotherapeutics (ARQT) has published positive long-term Phase 3 data for its ZORYVE (roflumilast) cream 0.05% for children aged 2 to 5 with mild-to-moderate atopic dermatitis. The INTEGUMENT-OLE study demonstrated the once-daily treatment's safety, tolerability, and sustained efficacy over 52 weeks, leading to its FDA approval in October 2025. The results showed significant skin clearance and itch reduction, with a favorable safety profile.
Arcutis (ARQT) Announces Long-Term Phase 3 Data for ZORYVE Cream in Children
Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) announced long-term Phase 3 data for ZORYVE (roflumilast) cream 0.05% in children aged 2 to 5 with mild-to-moderate atopic dermatitis, showing sustained efficacy and a favorable safety profile over 52 weeks. The INTEGUMENT-OLE study supported the FDA's October 2025 approval, providing a new nonsteroidal treatment option. Over 63% of children achieved 'Clear' or 'Almost Clear' skin, and proactive maintenance sustained disease control for approximately 8 months.
Arcutis Biotherapeutics (ARQT) Unveils New Trial Data at Dermatology Meeting
Arcutis Biotherapeutics (ARQT) is preparing to disclose new clinical data from its ZORYVE product line at the 2026 American Academy of Dermatology Annual Meeting. The presentations will cover findings on ZORYVE cream 0.05% for atopic dermatitis in infants, long-term caregiver-reported outcomes for children, and subgroup analyses for seborrheic dermatitis and plaque psoriasis. Despite strong revenue growth and high gross margins, the company faces negative net margins and free cash flow yield, but maintains a solid balance sheet and a positive analyst outlook.
New eczema treatment data in infants and kids set for 2026 AAD
Arcutis Biotherapeutics (Nasdaq: ARQT) announced it will present new clinical data for its ZORYVE (roflumilast) portfolio at the 2026 American Academy of Dermatology Annual Meeting. Key presentations will include late-breaking Phase 2 efficacy and safety results for ZORYVE cream 0.05% in infants aged 3 to less than 24 months with mild to moderate atopic dermatitis, as well as long-term caregiver-reported outcomes for children aged 2 to 5 years. Additionally, subgroup analyses and PASI outcomes from Phase 3 trials for seborrheic dermatitis and plaque psoriasis will be shared.
Arcutis Biotherapeutics, Inc. (ARQT) Eyes Pediatric Expansion for ZORYVE Cream
Arcutis Biotherapeutics, Inc. is looking to expand the use of its ZORYVE cream to pediatric patients. This move is part of the company's strategy to broaden the treatment's reach and addresses the need for effective therapies for younger individuals suffering from related conditions.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Consensus Rating of "Moderate Buy" from Analysts
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has received a consensus "Moderate Buy" rating from analysts, with an average twelve-month price target of $34.00. Several research firms have updated their ratings and price targets, including upgrades to "buy" and "hold" recommendations. The company recently reported strong quarterly earnings, surpassing analyst expectations for both EPS and revenue, but insiders have sold a significant number of shares.
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?
The article discusses whether Arcutis Biotherapeutics (ARQT) is underperforming the broader medical sector this year. It notes that ARQT's year-to-date return is -22.46%, while the Medical sector has seen a 2.50% gain and the S&P 500 a 7.74% gain. This suggests ARQT is significantly lagging its industry and the overall market.
Ally Bridge Group NY LLC Invests $4.40 Million in Arcutis Biotherapeutics, Inc. $ARQT
Ally Bridge Group NY LLC recently invested $4.40 million in Arcutis Biotherapeutics (NASDAQ:ARQT) by purchasing 233,220 shares. This investment constitutes 2.7% of Ally Bridge Group NY LLC's holdings and 0.19% of Arcutis Biotherapeutics. Despite insider sales totaling $4.54 million, analysts have a "Moderate Buy" rating for Arcutis, with an average price target of $34.
The Technical Signals Behind (ARQT) That Institutions Follow
This article analyzes the technical signals for Arcutis Biotherapeutics Inc. (ARQT) using AI models to suggest institutional trading strategies. It highlights a positive near-term sentiment within a long-term strength context, despite a weak mid-term bias. The analysis provides specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry, target, and stop-loss levels, along with multi-timeframe signal analysis for support and resistance.
Arcutis reports long-term data on eczema cream for young children
Arcutis Biotherapeutics announced long-term data from a Phase 3 study for its eczema cream, ZORYVE, in young children. The study, published in Pediatric Dermatology, supported the FDA approval of ZORYVE for children aged 2 to 5 years with mild-to-moderate atopic dermatitis, showing positive safety and efficacy results. The company has experienced significant revenue growth and analyst upgrades, with expectations to become profitable this year.
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2-5 in Pediatric Dermatology
Arcutis Biotherapeutics announced the publication of positive long-term safety and efficacy data for ZORYVE (roflumilast) cream 0.05% in treating mild-to-moderate atopic dermatitis in children aged 2-5. The data, published in Pediatric Dermatology, demonstrated the cream's safety, tolerability, and sustained efficacy for up to 56 weeks, supporting its use as a long-term treatment option for this pediatric population. Many participants achieved disease clearance, with some maintaining control for a median of approximately eight months on a proactive twice-weekly application.
Year-long eczema study: Arcutis cream eased symptoms in young kids
Arcutis (ARQT) has reported positive long-term Phase 3 open-label extension data for its ZORYVE cream 0.05% in children aged 2-5 with mild-to-moderate atopic dermatitis. The study, published in Pediatric Dermatology, showed durable efficacy through 56 weeks, with 63.1% achieving clear or almost clear skin and over 70% achieving a 75% reduction in Eczema Area and Severity Index (EASI-75). The cream demonstrated a favorable safety and tolerability profile, including high local tolerability and mostly mild or moderate adverse events.
Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline
Arcutis Biotherapeutics Inc (ARQT) has initiated a Phase 1a/1b clinical trial for ARQ-234, an injectable biologic medicine designed to treat moderate to severe atopic dermatitis. The study, which began dosing on March 2, 2026, focuses on the safety and pharmacokinetics of ARQ-234, with an update filed on March 6, 2026. This trial signifies Arcutis's expansion into new biologics, crucial for its long-term growth and competitiveness in the intense atopic dermatitis market.
Arcutis Biotherapeutics (ARQT) Is Down 11.0% After Raising 2026 Guidance and Turning Profitable - What's Changed
Arcutis Biotherapeutics (ARQT) reported strong Q4 2025 results with increased revenue and profitability, and raised its 2026 net product revenue guidance. The company is advancing its ARQ-234 atopic dermatitis program and promoting key personnel, signaling a shift towards a more mature commercial model beyond its ZORYVE franchise. However, investors still face concentration risk due to the company's reliance on ZORYVE for most of its revenue.
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
Arcutis Biotherapeutics has announced the promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer, in addition to his current role as corporate secretary. Mr. Matsuda will oversee the company's legal, compliance, and governance strategy, focusing on the growth of the ZORYVE portfolio and intellectual property protection. This promotion reflects his instrumental role in guiding Arcutis through significant commercial growth and multiple FDA approvals.
GW&K Investment Management LLC Sells 206,391 Shares of Arcutis Biotherapeutics, Inc. $ARQT
GW&K Investment Management LLC reduced its stake in Arcutis Biotherapeutics by selling 206,391 shares, now holding 0.96% ownership valued at $22.09 million. While GW&K decreased its position, other institutional investors like Perpetual Ltd and Jennison Associates LLC significantly increased their holdings. Insider selling also occurred, with executives disposing of 175,233 shares totaling $4.54 million over the last 90 days.
10 Fastest Growing NASDAQ Stocks to Buy
This article highlights Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) as one of the fastest-growing NASDAQ stocks. The company received raised price targets and maintained "Buy" ratings from Guggenheim and TD Cowen following strong Q4 2025 results and increased guidance. Arcutis saw significant year-over-year revenue growth due to demand for its product ZORYVE and is well-positioned for future growth.
Is Arcutis Biotherapeutics (ARQT) Pricing Reflecting Long Term Potential After Recent Pullback?
Arcutis Biotherapeutics (ARQT) has experienced mixed returns recently, though it's up significantly over one and three years. Simply Wall St's analysis suggests ARQT is undervalued, with a Discounted Cash Flow model indicating it's 73.4% below its intrinsic value and a Price/Sales ratio also pointing to a discount. The company, which specializes in dermatology treatments, has seen its stock price fluctuate due to market reactions to its commercial execution and drug adoption.
Arcutis Biotherapeutics (ARQT) exec sells shares and receives new equity awards
Arcutis Biotherapeutics executive Masaru Matsuda sold 12,058 shares of common stock in early March 2026 under a Rule 10b5-1 trading plan, with some sales covering tax withholding. Concurrently, he received significant equity compensation on February 27, 2026, including 97,000 stock options and 37,000 restricted stock units, which vest over several years contingent on his continued service. These transactions reflect both pre-planned stock sales and new compensatory awards for the executive.
Arcutis Promotes Mas Matsuda to Executive Vice President, Chief Legal Officer
Arcutis Biotherapeutics has promoted Mas Matsuda, JD, from senior vice president and general counsel to executive vice president and chief legal officer. Matsuda will continue to hold the title of corporate secretary and will lead the company's legal, compliance, and governance strategies, overseeing the commercialization of the Zoryve portfolio, intellectual property protection, and corporate transactions. This promotion comes as Arcutis focuses on expanding its presence in immuno-dermatology, building on the success of its Zoryve drug, which has received six FDA approvals for various dermatological conditions.
Arcutis Biotherapeutics Promotes Mas Matsuda to Executive Vice President and Chief Legal Officer
Arcutis Biotherapeutics has promoted Mas Matsuda to Executive Vice President, Chief Legal Officer, and Corporate Secretary. Matsuda, who previously served as General Counsel, will oversee the company's legal, compliance, and governance strategies, particularly as it expands its ZORYVE portfolio for inflammatory skin diseases. CEO Frank Watanabe lauded Matsuda's crucial role in the company's significant growth and multiple FDA approvals for ZORYVE.
Arcutis Announces Promotion of Mas Matsuda to Executive
Arcutis Biotherapeutics, Inc. has promoted Mas Matsuda to Executive Vice President, Chief Legal Officer, and Corporate Secretary. In this expanded role, Mr. Matsuda will continue to lead the company's legal, compliance, and governance strategies, supporting its growth and the commercialization of its ZORYVE portfolio. This promotion reflects Arcutis entering a new phase of growth and its commitment to advancing its immuno-dermatology innovations.
Arcutis Announces Promotion of Mas Matsuda to Executive
Arcutis Biotherapeutics has promoted Mas Matsuda to Executive Vice President and Chief Legal Officer, recognizing his significant contributions to the company's legal, compliance, and governance strategies. Matsuda has been instrumental in supporting the commercialization of the ZORYVE® portfolio and protecting intellectual property, guiding Arcutis through a period of substantial growth including six FDA approvals. His leadership is deemed crucial as the company enters its next phase of expansion and continues to advance its pipeline in immuno-dermatology.
ARQT SEC Filings - Arcutis Biotherapeutics, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors and traders seeking official regulatory documents for Arcutis Biotherapeutics, Inc. (ARQT), including 10-K, 10-Q, and 8-K forms, as well as insider trading information. It details the company's financial performance, governance, and progress in developing dermatological therapies, with AI-powered summaries to highlight key points. The article also includes recent SEC filings, such as an insider share sale by a board member.
Insider Sell Alert: Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT)
Howard Welgus, a Director at Arcutis Biotherapeutics Inc (ARQT), sold 10,000 shares of the company on March 2, 2026. This transaction brings his total holdings to 49,744 shares. The stock is currently trading at $25.65, with a GF Value of $28.01, indicating it is modestly undervalued.
Arcutis (ARQT) director sells 39,272 shares under 10b5-1 plan
Arcutis Biotherapeutics director Leonard Keith R reported exercising stock options and simultaneously selling 39,272 shares of common stock at a weighted average price of $25.392 per share. These transactions, which occurred on March 2, 2026, were conducted under a Rule 10b5-1 trading plan adopted in November 2025. Following these sales, he directly owns 22,123 Arcutis shares, with an additional 1,750 shares held indirectly by a family trust.
Vanguard Group Inc. Buys 96,991 Shares of Arcutis Biotherapeutics, Inc. $ARQT
Vanguard Group Inc. increased its stake in Arcutis Biotherapeutics, Inc. by 1.4%, acquiring an additional 96,991 shares and now owning 7,146,090 shares worth $134.7 million. Several other institutional investors also adjusted their positions in the company. The article notes recent insider selling, largely negative sentiment from several news stories, and mixed analyst ratings, with an average "Moderate Buy" rating and a consensus price target of $31.86.
